Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
Homo sapiens protein tyrosine kinase 2 (PTK2), transcript variant 1
Synonyms:
FADK; FAK; FAK1; FRNK; p125FAK; pp125FAK; PPP1R71
Immunogen
A phospho-specific peptide corresponding to residues surrounding Tyrosine 397 of human FAK was used as an immunogen. This antibody detects FAK phosphorylated at Y397.
Buffer
50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
Focal adhesion kinase (FAK) is a non-receptor protein-tyrosine kinase implicated in signaling pathways involved in cell motility, proliferation and apoptosis (1). FAK is composed of a central catalytic domain flanked by large N- and C-terminal regions. FAK is activated by phosphorylation at tyrosine 397 in response to integrin clustering which can be induced by cell adhesion or antibody cross-linking or via G-protein-coupled receptor (GPCR) occupancy by ligands such as bombesin or lysophosphatidic acid (2-3). Phosphorylation of FAK Tyr-397 creates a binding site for Src-family kinases, and phosphorylation of FAK Tyr-576/Tyr-577 in the kinase domain activation loop enhances catalytic activity (4). Increased FAK expression has been correlated with the enhanced motility and invasiveness of human tumor cells, as well as with promoting increased cell proliferation.
Related Pathway
Focal Adhesion
Hemostasis
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis on human brain tissue lysates (A, B) and rat brain tissue lysates (C, D) using anti-Phospho-Fak (pY397), 1:2000 dilution. Cells were either (A, C) untreated (B, D) treated with AP
Researchers who bought this antibody have also purchased:
